{
    "clinical_study": {
        "@rank": "57038", 
        "arm_group": [
            {
                "arm_group_label": "Olaparib+ paclitaxel", 
                "arm_group_type": "Experimental", 
                "description": "olaparib + paclitaxel"
            }, 
            {
                "arm_group_label": "Placebo+paclitaxel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo+ paclitaxel"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a phase III, multi-centre study of olaparib in combination with paclitaxel,\n      compared with placebo in combination with paclitaxel in patients with advanced gastric\n      cancer  who have progressed following first-line therapy. Patients will be from China, Japan\n      , Korea and Taiwan."
        }, 
        "brief_title": "Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "A  randomized, double-blinded, multicentre phase III study to access the efficacy and safety\n      of olaparib in combination with paclitaxel, compared with placebo in combination with\n      paclitaxel in Asian patients with advanced gastric cancer (including gastro-oesophageal\n      junction) who have progressed following first line therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced gastric cancer (including GEJ) that has progressed following first-line\n             therapy.\n\n          -  Patients must be \u226518 years of age.  Age \u226520 if Japanese\n\n          -  Provision of tumour sample (from either a resection or biopsy).\n\n          -  At least one lesion (measurable and/or non-measurable) that can be accurately\n             assessed by imaging (CT/MRI) at baseline and following up visits.\n\n        Exclusion Criteria:\n\n          -  More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant\n             chemotherapy with more than 6 month wash out period) for the treatment of gastric\n             cancer in the advanced setting.\n\n          -  Any previous treatment with a Polyadenosine 5'-diphosphoribose [poly-(ADP-ribose)]\n             polymerisation (PARP) inhibitor, including olaparib.\n\n          -  Patients with second primary cancer, except: adequately treated non-melanoma skin\n             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours\n             curatively treated with no evidence of disease for \u22655 years.\n\n          -  Human Epidermalgrowth Factor Receptor-2 (HER2) positive patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "629", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924533", 
            "org_study_id": "D081BC00004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Olaparib+ paclitaxel", 
                "description": "Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.", 
                "intervention_name": "Olaparib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Olaparib+ paclitaxel", 
                    "Placebo+paclitaxel"
                ], 
                "description": "IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo+paclitaxel", 
                "description": "Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chiba-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kasama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takatsuki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utsunomiya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anyang-si", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwasun-gun", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju-si", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam-si", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Xiaojin Shi", 
            "phone": "+86 21 60302409"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University, College of Medicine and Cancer Research Institute, Republic of Korea", 
            "last_name": "Yung-Jue Bang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Korea: Food and Drug Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Taiwan: Food and Drug Administration, Ministry of Health and Welfare"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924533"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years"
            }, 
            {
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years"
            }, 
            {
                "measure": "To investigate plasma exposure to olaparib in a subset of olaparib dosed patients in the presence of paclitaxel and assess the impact of previous gastric surgery on that exposure", 
                "safety_issue": "No", 
                "time_frame": "Blood samples (2 mL) for determination of olaparib in plasma will be taken at the times on pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours after first dose of study"
            }, 
            {
                "measure": "Time to deterioration of Health Related Quality of Life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 item module (QLQ-C30) global HRQoL scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-treatment , Day 29 and then every 4 weeks until discontinuation, assessed up to 3 years"
            }, 
            {
                "measure": "Assessment of Adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed up to 3 years"
            }, 
            {
                "measure": "Assessments of physical examination, vital signs (including blood pressure (BP) and pulse)", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed up to 3 years"
            }, 
            {
                "measure": "Assessment of electrocardiogram (ECG)(if clinically indicated)", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed up to 3 years"
            }, 
            {
                "measure": "Assessment of laboratory findings including clinical chemistry, haematology and urinalysis (if clinically indicated)", 
                "safety_issue": "Yes", 
                "time_frame": "Assessed up to 3 years"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}